Two trials will involve over 6,000 participants at sites in and outside the US

Therapy failed to improve invasive disease-free survival in high-risk patients

Oral S1P receptor modulator hit both primary endpoints in a phase III trial

Dovato demonstrated non-inferior efficacy compared to TAF-based regimens

Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients kblankenship Fri, 10/09/2020 – 13:50

Researchers used a second-generation pro-drug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice […]

Virologists have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in […]

Has Donald Trump launched a new space mission?For once this has nothing to do with the US president, […]

Hypertension is a harbinger of a huge cardiovascular disease burden globally, with an estimated one in three adults […]

Updated Date: Fri, 02 Oct 2020 00:00:00 EDT